Company intelligence
Isofol
Arfolitixorin - a new drug candidate for the treatment of colorectal cancer – one of the most common types of cancer.
Pharmaceutical Manufacturing
Gothenburg, SE
13 employees
Founded 2008
1 public signals
About Isofol
Isofol is a publicly listed biotech company developing the drug candidate arfolitixorin to enhance the efficacy of standard treatment for patients with severe forms of cancer. Our goal is s to have a central impact on tomorrow’s cancer treatment, giving more patients the opportunity to respond better to their treatment, improve their prognosis, and gain more time with life. Isofol’s share is listed on Nasdaq Stockholm.
Verified activity
Signals from Isofol
1 published signal